| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 7,690 | 7,880 | 5,730 | 1,260 | 230 |
| Sales Growth | -2.41% | +37.52% | +354.76% | +447.82% | +4.55% |
| Net Income | -63,120 | -69,200 | -88,100 | -98,590 | -60,730 |
| Net Income Growth | +8.79% | +21.45% | +10.64% | -62.34% | -99.18% |
Bolt Biotherapeutics Inc
(BOLT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Bolt Biotherapeutics Inc. is a clinical-stage immuno-oncology company. It engages in the discovery, development, and commercialization of pharmaceutical products. The company's principal product includes BDC-1001. Bolt Biotherapeutics Inc. is based in Redwood city, California.
Fiscal Year End Date: 12/31